Figure 5.

Combined treatment with BEZ235 and ruxolitinib reduces dissemination of leukaemic cells and improves survival in a JAK2V617F-driven mouse model. (A) SCID mice injected with 3 × 10⁶ JAK2V617F Ba/F3-EPOR luc⁺ cells were randomized 6 days later (baseline) into four treatment groups (vehicle, ruxolitinib [ruxo; 60 mpk], BEZ235 [45 mpk] and combination) based on baseline bioluminescence measurement. Further bioluminescence analysis was performed at weekly intervals. Images are from a representative experiment of three performed. (B) Bioluminescence activity (expressed as counts per minute, cpm; Mean ± SD of four to six mice/group in each experiment, n = 3) was measured on day 7 of treatment (day 13 after cells injection). (C) Kaplan–Meyer estimate of survival in mice injected with JAK2V617F Ba/F3-EPOR luc⁺ cells; treatment started on day 7 after injection. The survival of mice receiving combination treatment with BEZ235 and ruxolitinib was significantly improved compared with the other groups. *P < 0.05; **P < 0.01.